| Kelly Havig Smith, MD | |
|
30 Mt Highway 91 S, Dillon, MT 59725-3535 | |
| (406) 683-1188 | |
| Not Available |
| Full Name | Kelly Havig Smith |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 30 Mt Highway 91 S, Dillon, Montana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912137092 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 25642 (Montana) | Primary |
| Entity Name | Barrett Hospital Development Corporation |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1326042078 PECOS PAC ID: 4082904487 Enrollment ID: O20160928000919 |
News Archive
Hydrogels are often used as drug delivery systems, but to be effective carriers for anti-cancer drugs, they need to be responsive to varied stimuli in the tumor microenvironment.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 ("miR-103/107") for the treatment of Non Alcoholic Steatohepatitis ("NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics.
Pioglitazone - a drug used to treat type 2 diabetes - is associated with an increased risk of bladder cancer, finds a study published on bmj.com today.
Neurological problems during and after COVID-19 are persistent and frequent. However, research is still ongoing as to why certain people exhibit specific symptoms. Research led by Yi-Ping Hsueh from the Institute of Molecular Biology in Taiwan suggests SARS-CoV-2 infection in the brain could be sex-dependent.
› Verified 2 days ago
| Entity Name | Barrett Hospital Development Corporation |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1396286480 PECOS PAC ID: 4082904487 Enrollment ID: O20170223001015 |
News Archive
Hydrogels are often used as drug delivery systems, but to be effective carriers for anti-cancer drugs, they need to be responsive to varied stimuli in the tumor microenvironment.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 ("miR-103/107") for the treatment of Non Alcoholic Steatohepatitis ("NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics.
Pioglitazone - a drug used to treat type 2 diabetes - is associated with an increased risk of bladder cancer, finds a study published on bmj.com today.
Neurological problems during and after COVID-19 are persistent and frequent. However, research is still ongoing as to why certain people exhibit specific symptoms. Research led by Yi-Ping Hsueh from the Institute of Molecular Biology in Taiwan suggests SARS-CoV-2 infection in the brain could be sex-dependent.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelly Havig Smith, MD 600 Hwy 91 South, Dillon, MT 59725-7379 Ph: (406) 683-3000 | Kelly Havig Smith, MD 30 Mt Highway 91 S, Dillon, MT 59725-3535 Ph: (406) 683-1188 |
News Archive
Hydrogels are often used as drug delivery systems, but to be effective carriers for anti-cancer drugs, they need to be responsive to varied stimuli in the tumor microenvironment.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 ("miR-103/107") for the treatment of Non Alcoholic Steatohepatitis ("NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics.
Pioglitazone - a drug used to treat type 2 diabetes - is associated with an increased risk of bladder cancer, finds a study published on bmj.com today.
Neurological problems during and after COVID-19 are persistent and frequent. However, research is still ongoing as to why certain people exhibit specific symptoms. Research led by Yi-Ping Hsueh from the Institute of Molecular Biology in Taiwan suggests SARS-CoV-2 infection in the brain could be sex-dependent.
› Verified 2 days ago
Dr. Laura M Goodell, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 41 Barrett St, Dillon Community Health Center, Dillon, MT 59725 Phone: 406-683-4440 Fax: 406-683-1121 | |
Dr. Bruce T Hayward, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 600 Mt Highway 91 S, Dillon, MT 59725 Phone: 406-683-3000 | |
Dr. Megan M Evans, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 41 Barrett St, Dillon, MT 59725 Phone: 406-683-4440 Fax: 406-683-1121 | |
Hallie Ann Kerins Tipton, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 30 Mt Highway 91 S, Dillon, MT 59725 Phone: 406-683-1188 | |
John S Madany, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 30 Hwy 91 S, Suite 100, Dillon, MT 59725 Phone: 406-683-4440 | |
Dr. Burke E Hansen, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 30 Mt Highway 91 S, Suite 204, Dillon, MT 59725 Phone: 406-683-4252 Fax: 406-683-9403 |